UNSPSC 51262507: Guanoxan sulfate

This classification denotes a guanidine and antihypertensive agent 2C10H13N3O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N6IT80R85G, chemically known as (1,4-benzodioxan-2-yl-methyl)guanidine sulfate (2:1), but more generally known as guanoxan sulfate, which bears US NIH Compound Identifier 21942. European Medicines Agency schedules Guanoxan sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02432MIG.

Most nations, for tariff and trade purposes, schedule guanoxan sulfate under HS 29329985 and SITC 51569. As of Q4 2014, GUANOXAN SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)OCC(O2)CNC(=N)N.C1CCC2C(C1)OCC(O2)CNC(=N)N.OS(=O)(=O)O.

UNSPSC 51262507 Guanoxan sulfate is a Commodity code with sparse relevant recent activity in state and local procurement. The two opportunities posted under this code in the past ninety days—Seminole County's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions—are tangentially related to pharmaceutical products but do not align with the code's nominal scope of guanoxan sulfate, a vasodilator agent. Seminole County, Florida is the only issuing body showing concrete procurement activity, soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to its community health building. The Texas RFI represents exploratory market intelligence on pharmacy benefit program restructuring rather than a procurement of specific pharmaceutical commodities.

Geographic activity is concentrated in Florida and Texas based on recent postings, with no discernible pattern of multi-state solicitations under this code. Seminole County's IFB (solicitation number IFB60459723LAS) closed on July 26, 2023, and required vendors to submit electronic bids with all shipping and delivery costs included; the contract offered an initial two-year term with one-year renewal options and imposed E-Verify compliance, drug-free workplace certification, and specific insurance requirements. The code shows minimal state and local procurement momentum and likely represents a data-entry mismatch rather than active demand for guanoxan sulfate. Businesses evaluating this code should verify whether opportunities posted under it actually solicit guanoxan sulfate or related vasodilator pharmaceuticals before committing resources to pursuit.